Surgical Technologies
Medtronic Canada receives licence for Affera system, Sphere-9 catheter
October 30, 2026
BRAMPTON, ONT. – Medtronic Canada announced Health Canada license of the Affera™ Integrated Mapping System and Affera Ablation System with Sphere-9™ Catheter, 1.
At a presentation in Toronto, Dr. Jason Andrade, director of electrophysiology at the Vancouver General Hospital, observed that cardiac ablation has been shown to be a far better solution to treating atrial fibrillation than medication.
While ablation effectively targets the cause of cardiac fibrillation and restores the heart to regular rhythms, medication only addresses the symptoms. “Medications don’t change the trajectory of the disease, and the condition of the heart gets worse,” said Dr. Andrade.
Meanwhile, the wait lists for cardiac ablation continue to grow and the costs are rising. “In Canada, over $1 billion [annually] is spent on managing atrial fibrillation,” he noted. “Over 50 percent of that cost is hospitalization.”
That’s why, he said, it’s best to conduct cardiac ablation as early in the course of the disease as possible. By waiting, the disease progresses and the patient only gets worse – often leading to hospitalization.
As Dr. Andrade noted, those wait lists are not good for patients. “The disease is festering while patients should be getting treatment,” he asserted.
The benefit of Medtronic’s Affera system is that it enables physicians to treat different types of arrythmias using the same catheter. That allows them to perform their work faster – they don’t have to stop and start over using a different catheter.
It’s also less expensive, as they’re using one catheter for the procedure instead of two.
Vancouver General is the first site to use the Affera system in Canada. Dr. Andrade noted that it has recently been used in the US and Europe, and now Canadian hospitals – and patients – will obtain the benefits.
“The Affera system represents an important advancement for the treatment of atrial fibrillation and atrial flutter,” said Dr. Allan Skanes, director of Western University Heart Rhythm Program, London Health Sciences Centre, in a Medtronic news release.
“By combining high-density mapping and dual-energy ablation in a single catheter, this technology provides physicians with a versatile tool that can streamline procedures while maintaining strong safety and efficacy outcomes for patients.”
The Sphere-9 catheter features a novel lattice-tip design that enables both pulsed field and radiofrequency energy delivery and is fully integrated with the Affera Mapping and Ablation System.
This integration supports procedural efficiency by enabling a single transseptal, zero-fluoroscopy, and zero-exchange workflow, allowing physicians to map and ablate with one catheter.
“The Affera system was designed to address key procedural challenges faced by the electrophysiology community while maintaining a high standard of safety and efficacy for patients,” said Doron Harlev, vice president of engineering for Cardiac Ablation Solutions at Medtronic and founder of Affera. “Its ability to integrate mapping and ablation technologies and offer both pulsed field and radiofrequency energy provides physicians with meaningful flexibility in treating complex arrhythmias.”
The license is supported by results from the SPHERE Per-AF study, which evaluated the Sphere-9 catheter with the Affera Mapping and Ablation System compared with a conventional radiofrequency ablation catheter and mapping system. The Affera system received CE Mark in March 2023, FDA in October 2024, and has also been approved in other international markets.
“At Medtronic Canada, we are committed to bringing meaningful innovation to physicians and patients,” said Rob Clifton, president Medtronic Canada. “With the license of the Affera system in our country, we are excited to expand access to a novel mapping and ablation solution that can help physicians treat atrial fibrillation more safely, effectively, and efficiently.”
Atrial fibrillation (AFib) is one of the most common heart rhythm disorders worldwide, affecting more than 60 million people globally. In Canada, it is the most common sustained heart rhythm disorder, affecting about 3 percent of the general population – or more than 1 million Canadians, according to the Canadian Cardiovascular Society.
AFib prevalence heavily scales with age. While it affects around 1 percent of people under 50, that number rises to approximately 4 percent at 65 and jumps to 10-15 percent for those 80 and older. Similarly, as the disease advances, the risk of serious complications such as heart failure, stroke, and death increases.